SI
The startup develops anti-SEMA 3A therapies targeting ocular diseases such as diabetic macular edema and wet age-related macular degeneration. By providing protein inhibitors, the company enables physicians to treat these retinopathies and potentially address related neurodegenerative conditions.
Updated 18 months ago
Funding
$3.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SPFunding rounds are not available yet.
Founders
Product
Features
- The startup develops anti-SEMA 3A therapies targeting ocular diseases such as diabetic macular edema and wet age-related macular degeneration. By providing protein inhibitors, the company enables physicians to treat these retinopathies and potentially address related neurodegenerative conditions.